tofogliflozin

Asset

Selective SGLT2 inhibitor blocking renal glucose reabsorption

Stage: Phase 3
Modality: Small molecule
Target: SLC5A2; 1
Indication: 2
Trials: 1
Developer

Indications

1

Type 2 diabetes
Phase 3, Completed, NCT02537834, clinicaltrials.gov, 8 Oct 2026

In the full profile

Targets and what it contains1
Owner and partners1
Trials2
Evidence for its targets2
Competitors12
Aging relevance1

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 8 Oct 2026, 2 sources